BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 35196975)

  • 1. Practical Application of Rodent Transporter Knockout Models to Assess Brain Penetration in Drug Discovery.
    Eneberg E; Jones CR; Jensen T; Langthaler K; Bundgaard C
    Drug Metab Bioanal Lett; 2022; 15(1):12-21. PubMed ID: 35196975
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quantification of Transporter and Receptor Proteins in Dog Brain Capillaries and Choroid Plexus: Relevance for the Distribution in Brain and CSF of Selected BCRP and P-gp Substrates.
    Braun C; Sakamoto A; Fuchs H; Ishiguro N; Suzuki S; Cui Y; Klinder K; Watanabe M; Terasaki T; Sauer A
    Mol Pharm; 2017 Oct; 14(10):3436-3447. PubMed ID: 28880093
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Estimation of Fetal-to-Maternal Unbound Steady-State Plasma Concentration Ratio of P-Glycoprotein and/or Breast Cancer Resistance Protein Substrate Drugs Using a Maternal-Fetal Physiologically Based Pharmacokinetic Model.
    Peng J; Ladumor MK; Unadkat JD
    Drug Metab Dispos; 2022 May; 50(5):613-623. PubMed ID: 35149540
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quantitative investigation of the brain-to-cerebrospinal fluid unbound drug concentration ratio under steady-state conditions in rats using a pharmacokinetic model and scaling factors for active efflux transporters.
    Kodaira H; Kusuhara H; Fuse E; Ushiki J; Sugiyama Y
    Drug Metab Dispos; 2014 Jun; 42(6):983-9. PubMed ID: 24644297
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Species difference in brain penetration of P-gp and BCRP substrates among monkey, dog and mouse.
    Kido Y; Nanchi I; Fusamae Y; Matsuzaki T; Akazawa T; Sawada H; Iwasaki M; Nishida K; Tsuchiya E; Okuda T
    Drug Metab Pharmacokinet; 2022 Feb; 42():100426. PubMed ID: 34974334
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization and Validation of Canine P-Glycoprotein-Deficient MDCK II Cell Lines for Efflux Substrate Screening.
    Ye D; Harder A; Fang Z; Weinheimer M; Laplanche L; Mezler M
    Pharm Res; 2020 Sep; 37(10):194. PubMed ID: 32918191
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Experimental and Computational Methods to Assess Central Nervous System Penetration of Small Molecules.
    Gupta M; Feng J; Bhisetti G
    Molecules; 2024 Mar; 29(6):. PubMed ID: 38542901
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Muscle to Brain Partitioning as Measure of Transporter-Mediated Efflux at the Rat Blood-Brain Barrier and Its Implementation into Compound Optimization in Drug Discovery.
    Cui Y; Lotz R; Rapp H; Klinder K; Himstedt A; Sauer A
    Pharmaceutics; 2019 Nov; 11(11):. PubMed ID: 31718023
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Investigation of the role and quantitative impact of breast cancer resistance protein on drug distribution into brain and CSF in rats.
    Katagiri Y; Kawaguchi H; Umemura K; Tadano J; Miyawaki I; Takano M
    Drug Metab Pharmacokinet; 2022 Feb; 42():100430. PubMed ID: 34896751
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Screening novel CNS drug candidates for P-glycoprotein interactions using the cell line iP-gp: In vitro efflux ratios from iP-gp and MDCK-MDR1 monolayers compared to brain distribution data from mice.
    Ozgür B; Saaby L; Janfelt C; Langthaler K; Eneberg E; Jacobsen AM; Badolo L; Montanari D; Brodin B
    Eur J Pharm Biopharm; 2021 Dec; 169():211-219. PubMed ID: 34756975
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Integrating in Silico and in Vitro Approaches To Predict Drug Accessibility to the Central Nervous System.
    Zhang YY; Liu H; Summerfield SG; Luscombe CN; Sahi J
    Mol Pharm; 2016 May; 13(5):1540-50. PubMed ID: 27015243
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acyclovir Brain Disposition: Interactions with P-gp, Bcrp, Mrp2, and Oat3 at the Blood-Brain Barrier.
    Shan Y; Cen Y; Zhang Y; Tan R; Zhao J; Nie Z; Zhang J; Yu S
    Eur J Drug Metab Pharmacokinet; 2022 Mar; 47(2):279-289. PubMed ID: 35112329
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prediction of brain:blood unbound concentration ratios in CNS drug discovery employing in silico and in vitro model systems.
    Liu H; Dong K; Zhang W; Summerfield SG; Terstappen GC
    Drug Discov Today; 2018 Jul; 23(7):1357-1372. PubMed ID: 29548981
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recent advances in the in vitro and in vivo methods to assess impact of P-glycoprotein and breast cancer resistance protein transporters in central nervous system drug disposition.
    Chatterjee S; Deshpande AA; Shen H
    Biopharm Drug Dispos; 2023 Feb; 44(1):7-25. PubMed ID: 36692150
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prediction of Human Brain Penetration of P-glycoprotein and Breast Cancer Resistance Protein Substrates Using In Vitro Transporter Studies and Animal Models.
    Feng B; Doran AC; Di L; West MA; Osgood SM; Mancuso JY; Shaffer CL; Tremaine L; Liras J
    J Pharm Sci; 2018 Aug; 107(8):2225-2235. PubMed ID: 29608887
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Susceptibility of juvenile and adult blood-brain barrier to endothelin-1: regulation of P-glycoprotein and breast cancer resistance protein expression and transport activity.
    Harati R; Villégier AS; Banks WA; Mabondzo A
    J Neuroinflammation; 2012 Dec; 9():273. PubMed ID: 23253775
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Translational CNS Steady-State Drug Disposition Model in Rats, Monkeys, and Humans for Quantitative Prediction of Brain-to-Plasma and Cerebrospinal Fluid-to-Plasma Unbound Concentration Ratios.
    Sato S; Matsumiya K; Tohyama K; Kosugi Y
    AAPS J; 2021 Jun; 23(4):81. PubMed ID: 34085128
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of the breast cancer resistance protein (ABCG2) in the distribution of sorafenib to the brain.
    Agarwal S; Sane R; Ohlfest JR; Elmquist WF
    J Pharmacol Exp Ther; 2011 Jan; 336(1):223-33. PubMed ID: 20952483
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Examining the Uptake of Central Nervous System Drugs and Candidates across the Blood-Brain Barrier.
    Summerfield SG; Zhang Y; Liu H
    J Pharmacol Exp Ther; 2016 Aug; 358(2):294-305. PubMed ID: 27194478
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Successful Prediction of Fetal Exposure to Dual BCRP/P-gp Drug Substrates Using the Efflux Ratio-Relative Expression Factor Approach and PBPK M&S.
    Balhara A; Yin M; Unadkat JD
    Clin Pharmacol Ther; 2024 May; 115(5):1044-1053. PubMed ID: 38124355
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.